SEC Form 4 · accession 0001209191-15-029174
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D. Clayman
Officer — President and CEO · Director
Period of report
Mar 24, 2015
Accepted (ET)
Mar 25, 2015 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 24, 2015 | M | 5,000 | $0.1626 | A | 280,445 | D | |
| Common Stock | holding | — | — | — | 24,600 | I | By the Michael D. Clayman Irrevocable Trust | |
| Common StockF1 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, Fund |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2 | $0.1626 | Mar 24, 2015 | M | 5,000 | D | — | Sep 23, 2019 | Common Stock | 5,000 | 10,369 | D |
Explanation of responses
- F1Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.
- F2The stock option is fully vested and exercisable.